p53 is an independent prognostic factor for survival in thyroid cancer

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3993-3997

  Bachmann, Kai ^a   Pawliska, Denise ^a   Kaifi, Jussuf ^a   Schurr, Paulus ^a   Zörb, Jennifer ^a   Mann, Oliver ^a   Kahl, Hans J ^a   Izbicki, Jakob R ^a   Strate, Tim ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antigen; CM1; DO 7; p53; PAb 1801; Survival; Thyroid cancer

Indexed keywords

ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYROID CANCER;

ADULT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STAINING AND LABELING; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37649011768     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Goldman ND, Coniglio JU and Falk SA: Thyroid cancers. I. Papillary, follicular, and Hurthle cell. Otolaryngol. Clin North Am 29: 593-609, 1996.
2. Aldinger KA, Samaan NA, Ibanez M and Hill CS Jr: Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 41: 2267-2275, 1978.
3. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H and Samaan NA: Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66: 321-330, 1990.
4. Simon D, Goretzki PE, Gorelev V et al: Significance of P53 in human thyroid tumors. World J Surg 18: 535-540, 1994.
5. Caron de FC and Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes.Cancer 4: 1-15, 1992.
6. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
7. Hollstein M, Sidransky D, Vogelstein B and Harris CC: P53 mutations in human cancers. Science 253: 49-53, 1991.
8. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nat 351: 453-456, 1991.
9. Vogelstein B: Cancer. A deadly inheritance. Nat 348: 681-682, 1990.
10. Finlay CA, Hinds PW and Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
11. Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327, 1993.
12. Lane DP and Benchimol S: P53: oncogene or anti-oncogene? Genes Dev 4: 1-8, 1990.
13. Bartek J, Iggo R, Gannon J and Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893-899, 1990.
14. Nigro JM, Baker SJ, Preisinger AC et al: Mutations in the p53 gene occur in diverse human tumour types. Nat 342: 705-708, 1989.
15. Hollstein M, Soussi T, Thomas G, von Brevern MC and Bartsch: P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143: 369-389, 1997.
16. Godballe C, Asschenfeldt P, Jorgensen KE et al: Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 108: 243-249, 1998.
17. Wittekind Ch MH-JBFH. UICC (2002) TNM Klassifikation maligner Tumoren, 6.Aufl. Springer, Berlin Heidelberg New York, pp. 49-52, 2002.
18. Wittekind Ch KMSL. TNM Atlas. Illustrierter Leitfaden zur TNM/pTNM-Klassifikation maligner Tumoren. Springer, Berlin pp. 2511-2516, 2005.
19. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D and Barnes DM: Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J.Cell Sci 101(Pt 1): 183-189, 1992.
20. Vojtesek B, Bartek J, Midgley CA and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244, 1992.
21. Hsu SM, Raine L and Fanger H: A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734-738, 1981.
22. Hsu SM, Raine L and Fanger H: The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 75: 816-821, 1981.
23. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
24. Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428, 1994.
25. Robbins J, Merino MJ, Boice JD Jr et al: Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115: 133-147, 1991.
26. Herrera MF, Lopez-Graniel CM, Saldana J et al: Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 20: 94-99, 1996.
27. Sobin LH, Hermanek P and Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer 61: 2310-2314, 1988.
28. Hermanek P, Scheibe O, Spiessl B and Wagner G: TNM classification of malignant tumors: the new 1987 edition. Rontgenblatter 40(200): 1-10, 1987.
29. Tennvall J, Biorklund A, Moller T, Ranstam J and Akerman M: Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up. Cancer 57: 1405-1414, 1986.
30. Nishida T, Nakao K, Hamaji M, Nakahara MA and Tsujimoto M: Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 119: 568-575, 1996.
31. Ho YS, Tseng SC, Chin TY, Hsieh LL and Lin JD: P53 gene mutation in thyroid carcinoma. Cancer Lett 103: 57-63, 1996.
32. Milner J: The role of p53 in the normal control of cell proliferation. Curr.Opin.Cell Biol 3: 282-286, 1991.
33. Hinds PW, Finlay CA, Quartin RS et al: Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1: 571-580, 1990.
34. Donghi R, Longoni A, Pilotti S, Michieli P, Della PG and Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753-1760, 1993.
35. Papakosta V, Vairaktaris E, Vylliotis A et al: The co-expression of c-myc and p53 increases and reaches a plateau early in oral oncogenesis. Anticancer Res 26: 2957-2962, 2006.